Oragenics (NYSE:OGEN) Research Coverage Started at StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of Oragenics (NYSE:OGEN) in a report issued on Thursday. The brokerage set a “sell” rating on the stock.

Oragenics Stock Performance

OGEN stock opened at $1.01 on Thursday. Oragenics has a one year low of $0.97 and a one year high of $7.74. The company has a market capitalization of $4.52 million, a PE ratio of -0.12 and a beta of 0.58. The stock’s fifty day moving average is $1.61.

Oragenics (NYSE:OGEN) last posted its earnings results on Wednesday, May 15th. The company reported ($0.70) earnings per share for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Oragenics stock. Virtu Financial LLC purchased a new position in shares of Oragenics, Inc. (NYSE:OGEN) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned about 0.51% of Oragenics at the end of the most recent quarter. 18.71% of the stock is owned by institutional investors.

Oragenics Company Profile

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.